MYCOPLASMA IGG
Device Facts
| Record ID | K033064 |
|---|---|
| Device Name | MYCOPLASMA IGG |
| Applicant | Trinity Biotech USA |
| Product Code | LON · Microbiology |
| Decision Date | Nov 26, 2003 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 866.1645 |
| Device Class | Class 2 |
| Attributes | Real-World Evidence |
Real-World Evidence
| Submission | Device | Sponsor | RWD Sources | RWE Use Summary | Key Tags |
|---|---|---|---|---|---|
| K033064 · Nov 26, 2003 | MYCOPLASMA IGG | Trinity Biotech USA | Retrospective frozen serum samples from normal individuals | Retrospective serum samples were used to compare the performance of the Trinity Biotech Mycoplasma IgG ELISA against a commercial IFA kit to establish substantial equivalence. | Retrospective sera; Performance comparison; Substantial equivalence |
Clinical Evidence
| Study Design | Population | Comparator | Key Endpoints |
|---|---|---|---|
| Comparison of Trinity Biotech Mycoplasma IgG ELISA and IFA Study 1; Retrospective comparative study | Normal individuals of various ages and genders from Lyme disease endemic and non-endemic areas; Sample Size: 187; Number of Sites: 2 | Commercial IFA kit | % Agreement positive, % Agreement negative |
| Comparison of Trinity Biotech Mycoplasma IgG ELISA and IFA Study 2; Retrospective comparative study | Normal individuals of various ages, gender, and geographical location; Sample Size: 176; Number of Sites: 1 | Commercial IFA kit | % Agreement positive, % Agreement negative |
Indications for Use
The Trinity Biotech Captia™ Mycoplasma IgG ELISA kit is an Enzyme-Linked Immunosorbent Assay (ELISA) for semi-quantitative or qualitative determination of IgG antibodies in human serum to Mycoplasma pneumoniae for the determination of immunological experience. The Mycoplasma IgG ELISA kit may be used to evaluate paired sera for seroconversions and the presence of a significant increase in specific IgG as and aid in the diagnosis of Mycoplasma pneumoniae infection in the adult population.
Device Story
The Captia Mycoplasma IgG ELISA is an in vitro diagnostic test for human serum. It utilizes purified Mycoplasma pneumoniae antigen immobilized on microtiter wells. Patient serum is added; if specific IgG antibodies are present, they bind to the antigen. After washing, enzyme-labeled anti-human IgG is added, followed by a substrate solution. The resulting color change is measured photometrically, providing an indirect measurement of antibody concentration. The test is performed in clinical laboratories by trained technicians. Results are used by physicians to aid in the diagnosis of Mycoplasma pneumoniae infection by identifying seroconversion or significant antibody increases in paired acute and convalescent serum samples. The device provides semi-quantitative or qualitative results to assess patient immunological experience.
Clinical Evidence
No clinical data provided. Device is a distributor name change for a previously cleared predicate (K971393); performance characteristics were established in the predicate submission.
Technological Characteristics
Enzyme-Linked Immunosorbent Assay (ELISA) using purified Mycoplasma pneumoniae antigen coated on solid-phase microtiter wells. Employs enzyme-labeled anti-human IgG conjugate and substrate for photometric detection. Designed for semi-quantitative or qualitative analysis. Standard laboratory equipment required for photometric measurement.
Indications for Use
Indicated for adult population to detect IgG antibodies to Mycoplasma pneumoniae in human serum to determine immunological experience and aid in diagnosis of infection via evaluation of paired sera for seroconversion or significant IgG increase.
Regulatory Classification
Identification
A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.
Special Controls
*Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
Predicate Devices
- Mycoplasma IgG ELISA Test Kit (K971393)